{"id":"W2987552010","doi":"10.1182/blood-2019-128404","title":"ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology","funders":"","keywords":"Medicine; Internal medicine; Chlorambucil; Gastroenterology; Clinical endpoint; Neutropenia; Obinutuzumab; Phases of clinical research; Adverse effect; Chronic lymphocytic leukemia; Pharmacology; Clinical trial; Leukemia; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003140803,0.0007288535,0.00172766,0.000441037,0.0000922781,0.0000491741,0.0004598957,0.0002419476,0.0003908841],"category_scores_gemma":[0.0001026141,0.0004647449,0.000117865,0.001282073,0.0002641844,0.0002322482,0.0001917647,0.000387794,0.000213482],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1366327,"about_ca_system_score_gemma":0.06777032,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006888743,"about_ca_topic_score_gemma":0.0021026,"domain_scores_codex":[0.9949236,0.0001757302,0.0009184892,0.001138718,0.001648279,0.001195181],"domain_scores_gemma":[0.9968725,0.000281609,0.0004045579,0.001609626,0.0004078178,0.0004239065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5918795,0.08273696,0.2495935,0.005240117,0.01252381,0.01251663,0.02348252,0.008516665,0.002554805,0.00008558852,0.0004773945,0.0103925],"study_design_scores_gemma":[0.822529,0.1420307,0.01035253,0.0009431696,0.001133096,0.0002381522,0.001264656,0.01129703,0.009422431,0.000003190619,0.0001803842,0.0006056659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925452,0.000156624,0.000002606811,0.00002094784,0.00008349316,0.006377477,0.00004324912,0.0001234092,0.000647003],"genre_scores_gemma":[0.9962123,0.00007893407,0.00009639808,0.00006355776,0.00009139404,0.0003494439,0.000164428,0.0001596282,0.002783941],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.239241,"threshold_uncertainty_score":0.9997804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01791496854483397,"score_gpt":0.2841616989684662,"score_spread":0.2662467304236322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}